In This Issue:
Investor Q&A; Key Regulatory Issues for Strategic Life Sciences Partnerships in China; Compulsory Patent Licensing in China; and New Developments on the “Patentable Subject Matter” Requirement of U.S. Patent Law.
Excerpt from Investor Q&A -
Dr. Dan Zhang has more than ten years of drug development experience. He is the Chief Executive Officer of Fountain Medical Development, a full-service clinical CRO company based in South East Asia and China. Previously, Dr. Zhang was the head of clinical development and global safety assessment at Sigma-Tau Research Inc., a Vice President at the Quintiles Transnational Corp., and the Chairman of the Board at Quintiles Medical Development (Shanghai) Company Ltd.
Please see full issue below for more information.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.